Special Issue "State-of-the-Art Drug Discovery in the USA"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 233
Interests: biosimilars; mRNA delivery; AI-driven protein structure; bioequivalence; pharmacokinetics
Special Issues, Collections and Topics in MDPI journals
Modes of drug discovery shift over time; the new path engages digital technologies, AI drug design, modeling-based safety, and efficacy determination. The class of new drugs now comprises biological proteins, gene and cell therapy, and gene editing. mRNA vaccines and protein translation is changing the scope, returning the delivery to body cells instead of pills and injections. The AlphaFold capability to predict most complex structures, including proteins and receptors, will facilitate the creation of new drugs that had no treatment, such as the autoimmune disorders. This involves bringing the most creative minds together to share their perspectives and motivate young researchers and corporate research.
Therefore, we invite all authors actively contributing to drug discovery and development in the USA to participate in this Special Issue. Original research articles and reviews dealing with new strategies with the potential to provide novel treatments in the short term will be welcomed, as will manuscripts dealing with the hottest topics in drug discovery and cutting-edge methodological advances, including emerging industry trends and strategies in relationship with recent drug approvals.
Prof. Dr. Sarfaraz K. Niazi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- mRNA vaccines, mRNA therapeutic products
- in vitro modeling
- gene therapy
- gene editing
- cell therapy
- AI-based drug-receptor testing
- autoimmune disorders